Login to Your Account



QuatRx Secures $28M In Series C Round For Product Development

By Aaron Lorenzo


Wednesday, June 11, 2003
Just weeks after in-licensing a series of cholesterol-related compounds, QuatRx Pharmaceuticals Co. raised $28 million in venture capital financing. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription